ArticleACS omega2025
Global Profiling of the Proteome and Acetylome in Mice with Abdominal Aortic Aneurysms.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal aortic aneurysm (AAA) is a fatal vascular disease with a high rupture risk, and current treatments rely mainly on surgery. Pharmacological therapies are limited due to an incomplete understanding of disease mechanisms. This study aimed to identify potential targets for pharmacological intervention in AAA using a mouse model, focusing on proteomic and acetylomic alterations in aortic tissues. We successfully established a mouse AAA model and performed global proteomic and acetylomic analyses, identifying 7858 quantifiable proteins and 1790 acetylated proteins with 4581 acetylation sites. Bioinformatics analyses revealed that histones were enriched in pathways co-regulated by the proteome and acetylome and were modulated by histone acetyltransferases and deacetylases. Sirt2 and Sirt5 were predicted to inhibit neutrophil extracellular trap (NET) formation by suppressing histone acetylation, thereby potentially attenuating the progression of AAA. This study proposes that Sirt2 and Sirt5 may inhibit neutrophil extracellular trap (NET) formation by suppressing histone acetylation, potentially slowing AAA progression. Sirt2 and Sirt5 may represent potential therapeutic targets, providing a foundation for exploring the effect of the sirtuin protein family on AAA treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.